Drugs / H3B-6545
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04568902 | Sep 2020 → Oct 2025 | breast cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04288089 | Apr 2020 → Sep 2022 overdue | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | Eisai Inc. | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03250676 | Aug 2017 → Oct 2023 | breast adenocarcinoma, estrogen-receptor positive breast cancer, female breast carcinoma | Eisai Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H3B-6545 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04568902 ↗ |
| Action | Inhibit | “H3B-6545 (a novel selective ER covalent antagonist that inactivates wild-type and mutant ERα)” PMID 40830892 ↗ Aug 2025 |
| Modality | Small molecule | — CHEMBL5425361 ↗ |
| Route | Oral | “Oral capsules by mouth once daily” NCT03250676 ↗ |
| Target | ESR1 | “H3B-6545 is an ERα covalent antagonist that exhibits encouraging preclinical activity against CDK4/6i naïve and resistant ERαWT and ERαMUT tumors.” PMID 35642432 ↗ Jun 2022 |